TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 333906

Group type: EXPERIMENTAL
Intervention: Bovine lung heparin (2 units/ml)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Porcine intestinal heparin (2 units/ml)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride solution without heparin)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Comparison of bovine lung heparin and porcine intestinal heparin
Number of subjects: 64
Study: 29205686

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lower forearm median nerve block (group U)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anatomic landmark-based blocking (group T)
Number of subjects: 100
Study: 27806971

Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) - 25% of energy requirements (2.3 ± 0.3 MJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Energy balance - 100% of energy requirements (9.3 ± 1.3 MJ)
Number of subjects: 18
Study: 25115230

Group type: EXPERIMENTAL
Intervention: Grandio (nanohybrid composite)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: QuiXfil (microhybrid composite)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both Grandio and QuiXfil
Number of subjects: 31
Study: 22468992

Group type: EXPERIMENTAL
Intervention: Feedback intervention
Number of subjects: 413

Group type: COMPARATOR
Intervention: No-feedback control
Number of subjects: 413
Study: 20687931

Group type: EXPERIMENTAL
Intervention: Polypill-based strategy (single capsule containing aspirin, a statin, and two blood pressure-lowering agents)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Polypill-based strategy
Number of subjects: 1000
Study: 18272344

Group type: EXPERIMENTAL
Intervention: Serrapeptase 5mg + 1000 mg paracetamol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + 1000 mg paracetamol
Number of subjects: 24
Study: 16167356

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg twice a day for 3 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (identical in appearance to caffeine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12957423

Group type: EXPERIMENTAL
Intervention: Repeat stenting
Number of subjects: 450

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Repeat stenting in large vessels (≥3 mm)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Balloon angioplasty in large vessels (≥3 mm)
Number of subjects: 450
Study: 10798512

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (OBIWOM training program)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 10
Study: 8719123

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: pimozide 1 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: pimozide 2 mg
Number of subjects: 10
Study: 1389818

Group type: EXPERIMENTAL
Intervention: Top-ups of 0.25% bupivacaine (group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Infusion of 0.125% bupivacaine (group B)
Number of subjects: 80
Study: 3885918

Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E2 (PGE2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 28631234

Group type: EXPERIMENTAL
Intervention: Implementation quality and participant responsiveness
Number of subjects: 1721

Group type: EXPERIMENTAL
Intervention: Higher dosage of the PATHS curriculum
Number of subjects: 1721

Group type: EXPERIMENTAL
Intervention: Procedural fidelity and reach
Number of subjects: 1721
Study: 27486124

Group type: EXPERIMENTAL
Intervention: Adapted Falls Management Exercise (FaME) programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual activity (Control)
Number of subjects: 80
Study: 24939489

Group type: COMPARATOR
Intervention: Sevoflurane alone (1.3 MAC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC) + low-dose i.v. remifentanil (0.028 μg/kg per minute)
Number of subjects: 50
Study: 22898122

Group type: EXPERIMENTAL
Intervention: Point-of-choice prompting software on PC for 5 workdays
Number of subjects: 28

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 28
Study: 20685927

Group type: EXPERIMENTAL
Intervention: Bimanual movement context with active movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dynamic or visuomotor perturbation in one bimanual context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive movement of one arm
Number of subjects: 0
Study: 18661509

Group type: EXPERIMENTAL
Intervention: Communication Skill Training (CST) for nurses
Number of subjects: 89
Study: 15943844

Group type: EXPERIMENTAL
Intervention: Mosapride 15 mg/day
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Tandospirone 30 mg/day
Number of subjects: 64
Study: 12182218

Group type: EXPERIMENTAL
Intervention: Night-vision goggles (NVGs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No night-vision goggles (no NVGs)
Number of subjects: 0
Study: 10568628

Group type: EXPERIMENTAL
Intervention: Six types of visual analogue scales (VAS): simple, middle-marked, graphic rating, graduated, graduated-numbered, and numerical rating
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Horizontal and vertical orientations of VAS
Number of subjects: 870
Study: 8739808

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg twice daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1837713

Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 4081

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4081
Study: 6354904

Group type: EXPERIMENTAL
Intervention: Quinacrine hydrochloride
Number of subjects: 0
Study: 30707710

Group type: EXPERIMENTAL
Intervention: AlgoS (crisis cards for first-time attempters)
Number of subjects: 520

Group type: COMPARATOR
Intervention: TAU (Treatment as usual)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: AlgoS (phone calls for non-first attempters)
Number of subjects: 520
Study: 28070602

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (S34, S44, PC5) after NSAID intake
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control acupuncture (nonspecific points) after NSAID intake
Number of subjects: 46

Group type: COMPARATOR
Intervention: Drug-based treatment (NSAIDs only)
Number of subjects: 46
Study: 27115567

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine (CisGem)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Gemcitabine alone (Gem)
Number of subjects: 410
Study: 25374434

Group type: EXPERIMENTAL
Intervention: GlucoRx Nexus TD-4280 blood glucose monitoring system
Number of subjects: 105
Study: 22912474

Group type: EXPERIMENTAL
Intervention: Neutralized sunflower soapstock (NSS)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Soybean oil (SO)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Dietary fat levels (2%, 4%, 6%)
Number of subjects: 750
Study: 19513783

Group type: EXPERIMENTAL
Intervention: Partial splenic embolization (PSE) using polyvinyl alcohol particles to achieve embolization of at least 50% of the distal branches of the splenic artery.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Splenectomy with or without devascularization and left gastric ligation.
Number of subjects: 40
Study: 18158850

Group type: EXPERIMENTAL
Intervention: NanoSolve formulation (100 mg of CoQ(10) and 120 mg of vitamin E)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pure substances in hard gelatin capsules (reference)
Number of subjects: 24
Study: 15867044

Group type: EXPERIMENTAL
Intervention: CCK‐OP (0.04 mug/kg per dose, twice daily)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: CCK‐OP
Number of subjects: 243
Study: 12409567

Group type: EXPERIMENTAL
Intervention: Antireflux stent
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard open stent
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9876788

Group type: EXPERIMENTAL
Intervention: Propofol with air
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isoflurane with nitrous oxide
Number of subjects: 64
Study: 7543598

Group type: EXPERIMENTAL
Intervention: Zanoterone 200 mg
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Zanoterone (100 to 800 mg)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 1298631

Group type: EXPERIMENTAL
Intervention: Quinine loading dose of 20 mg/kg in 500 mls of normal saline or 5% dextrose infused over 4 hours followed by 100mg/kg infused 8 hourly for at least 24 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Oral quinine bisulfate 10mg/kg 8 hourly for a total of 7 days when patients were well enough (after initial loading dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard treatment without initial loading dose
Number of subjects: 17
Study: 6470965

Group type: EXPERIMENTAL
Intervention: Once daily (3000 mg of salicylate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice daily (1500 mg of salicylate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dosage schedules
Number of subjects: 0
Study: 30772699

Group type: EXPERIMENTAL
Intervention: Continuous care intervention (CCI) emphasizing nutritional ketosis
Number of subjects: 378

Group type: COMPARATOR
Intervention: Usual care (UC) treatment
Number of subjects: 378
Study: 30025007

Group type: EXPERIMENTAL
Intervention: Laser-modified abutments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Machined abutments
Number of subjects: 20
Study: 26952094

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg primaquine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 24045403

Group type: EXPERIMENTAL
Intervention: Systolic BP target of <150 mm Hg
Number of subjects: 65

Group type: COMPARATOR
Intervention: Systolic BP target of <180 mm Hg (control group)
Number of subjects: 65
Study: 22409262

Group type: EXPERIMENTAL
Intervention: 5 mg apixaban
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 10 mg apixaban
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 20 mg apixaban
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 19135657

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/d for 12 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Triptorelin (3.75 mg/mo for 12 weeks)
Number of subjects: 70
Study: 18007100

Group type: EXPERIMENTAL
Intervention: Fluor Protector fluoride varnish
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 15632931

Group type: EXPERIMENTAL
Intervention: New pneumatic nasal tamponade (Rapid Rhino)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choanal balloon tamponade
Number of subjects: 0
Study: 12183351

Group type: EXPERIMENTAL
Intervention: Subcutaneous infusion of lisuride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral levodopa and dopamine agonists (control)
Number of subjects: 0
Study: 9209645

Group type: EXPERIMENTAL
Intervention: p18 gene deletion or rearrangement in MCL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: p18 abnormalities in MCL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: p53 mutations and deletions of CDKI p15 and p16 in MCL
Number of subjects: 60
Study: 8358449

Group type: EXPERIMENTAL
Intervention: SUZI (Subzonal Insemination)
Number of subjects: 2

Group type: COMPARATOR
Intervention: ZD (Zonal Dissection)
Number of subjects: 2
Study: 3689626

Group type: EXPERIMENTAL
Intervention: DPI 201-106 (30 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DPI 201-106 (60 mg)
Number of subjects: 20
Study: 30087742

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 44
Study: 27331587

Group type: EXPERIMENTAL
Intervention: Standard Sizing arm (14 sizes available)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Modified Sizing arm (7 sizes available)
Number of subjects: 496
Study: 24796041

Group type: EXPERIMENTAL
Intervention: Acupuncture + rehabilitation (including hyperbaric oxygen and cognitive rehabilitation training)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Rehabilitation (including hyperbaric oxygen and cognitive rehabilitation training)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Acupuncture + rehabilitation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 73
Study: 22678640

Group type: EXPERIMENTAL
Intervention: Nasal and nasopharyngeal irrigation
Number of subjects: 2905
Study: 20388917

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1800 mg/d intravenously and ciprofloxacin 2 × 200 mg/d intravenously
Number of subjects: 102

Group type: COMPARATOR
Intervention: Physiological saline and ciprofloxacin 2 × 200 mg/d intravenously (placebo group)
Number of subjects: 102
Study: 18427974

Group type: EXPERIMENTAL
Intervention: Letrozole 5 mg/day (n = 70) on days 3-7 of the menstrual cycles
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day combined with human menopausal gonadotropin (hMG) 75 IU/ml
Number of subjects: 140
Study: 15671128

Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12841697

Group type: EXPERIMENTAL
Intervention: 50 microg vaginal misoprostol 6 hourly (group 1, n = 60)
Number of subjects: 120
Study: 10783352

Group type: EXPERIMENTAL
Intervention: Zona-free embryos (Group A: 27 women; Group B: 30 women)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Zona-intact embryos (Group A: 25 women; Group B: 41 women)
Number of subjects: 123
Study: 8842658

Group type: EXPERIMENTAL
Intervention: 33% oxygen in nitrous oxide
Number of subjects: 101

Group type: COMPARATOR
Intervention: 33% oxygen in air
Number of subjects: 101
Study: 1400933

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) buserelin stopped on the same day as HMG treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: GnRH agonist (GnRHa) buserelin continued during HMG treatment
Number of subjects: 63
Study: 3890510

Group type: EXPERIMENTAL
Intervention: Propafenone (300 mg every 12 hours during low-dose week, 300 mg every 8 hours during high-dose week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Quinidine (200 mg every 6 hours during low-dose week, 400 mg every 6 hours during high-dose week)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 25
Study: 31653476

Group type: EXPERIMENTAL
Intervention: Behavioral intervention focusing on relationship processes (relationship satisfaction, positive problem-solving)
Number of subjects: 268
Study: 29905631

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided block (USG) with 1% mepivacaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional block with 1% mepivacaine
Number of subjects: 84
Study: 27912951

Group type: EXPERIMENTAL
Intervention: Homeopathic cold syrup
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 24418164

Group type: EXPERIMENTAL
Intervention: Managed Ventricular Pacing (MVP)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Conventional Dual-Chamber Pacing (DDD)
Number of subjects: 605
Study: 21701811

Group type: EXPERIMENTAL
Intervention: Overweight Training (OT) group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Overweight Detraining (OD) group
Number of subjects: 39
Study: 20500881

Group type: EXPERIMENTAL
Intervention: Peer support intervention (2 hours of contact per fortnight for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19026272

Group type: EXPERIMENTAL
Intervention: Pragmatic trials of bipolar disorder treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study: 16019355

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg plus estradiol valerate 2 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus estradiol valerate 2 mg daily
Number of subjects: 50
Study: 12072848

Group type: EXPERIMENTAL
Intervention: Sitting motion palpation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Prone motion palpation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Paraspinal palpation for tenderness
Number of subjects: 85
Study: 9925834

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg once daily (QD)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.25 mg twice a day (BID)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg BID
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg QD
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 7753566

Group type: EXPERIMENTAL
Intervention: Closed ring apparatus (Ace Medical, Los Angeles, California)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Open ring device (Bremer, Inc, Jacksonville, Florida)
Number of subjects: 24
Study: 2307249

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) with cryopreserved sperm
Number of subjects: 154

Group type: COMPARATOR
Intervention: Intracervical insemination (ICI) with cryopreserved sperm
Number of subjects: 154
Study: 656715

Group type: EXPERIMENTAL
Intervention: In-patient treatment for three months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: In-patient treatment for six months
Number of subjects: 32
Study: 30791083

Group type: EXPERIMENTAL
Intervention: Dental splint (1-2 mm thick)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No dental splint
Number of subjects: 22
Study: 28257617

Group type: EXPERIMENTAL
Intervention: 2 sessions of range‐of‐motion exercises plus 6 sessions of stretching and strengthening exercises (exercise group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 2 sessions of cervicothoracic manipulation and range‐of‐motion exercises followed by 6 sessions of stretching and strengthening exercise (manipulative‐therapy‐plus‐exercise group)
Number of subjects: 140
Study: 25951477

Group type: EXPERIMENTAL
Intervention: Daily cleaning with multipurpose disinfection solution (MPDS)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control (no daily cleaning)
Number of subjects: 193
Study: 23860695

Group type: EXPERIMENTAL
Intervention: Desflurane (Group D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Group D and Group S
Number of subjects: 80
Study: 20643989

Group type: EXPERIMENTAL
Intervention: One-on-one advance planning intervention consisting of counseling and completing an advance directive with a social worker
Number of subjects: 262

Group type: COMPARATOR
Intervention: Minimal, self-guided intervention consisting of advance directive forms and written educational information
Number of subjects: 262
Study: 18327066

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 126137

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 126137

Group type: COMPARATOR
Intervention: Beta-adrenergic blockers
Number of subjects: 126137

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 126137

Group type: COMPARATOR
Intervention: Calcium channel blockers
Number of subjects: 126137

Group type: EXPERIMENTAL
Intervention: Placebo/untreated control
Number of subjects: 126137
Study: 15898290

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate 0.12% foam
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vehicle foam
Number of subjects: 19
Study: 12828818

Group type: EXPERIMENTAL
Intervention: Bolus Calculator (Medtronic MiniMed)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard Bolus
Number of subjects: 49
Study: 10823362

Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 4526

Group type: COMPARATOR
Intervention: Comparator NSAIDs
Number of subjects: 4526
Study: 9340416

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with tunnel incision (5 mm, no sutures)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with tunnel incision (8 mm, single sutures)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (scleral flap incision, double continuous sutures)
Number of subjects: 92
Study: 2050179

Group type: EXPERIMENTAL
Intervention: Doryx' (100 mg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vibramycin' (100 mg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 6134467

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerin spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained release transmucosal nitroglycerin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 percent nitroglycerin ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting nitrates
Number of subjects: 0
Study: 29436371

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 100
Study: 26518211

Group type: EXPERIMENTAL
Intervention: MPT (melphalan, prednisone, and thalidomide)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CTD (cyclophosphamide, thalidomide, and dexamethasone)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: TD (thalidomide and dexamethasone)
Number of subjects: 82

Group type: COMPARATOR
Intervention: MPT
Number of subjects: 82

Group type: COMPARATOR
Intervention: CTD
Number of subjects: 82

Group type: COMPARATOR
Intervention: TD
Number of subjects: 82
Study: 24399088

Group type: EXPERIMENTAL
Intervention: Ampicillin or Amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalosporin and Macrolide
Number of subjects: 0
Study: 23525934

Group type: EXPERIMENTAL
Intervention: DAA (24 μg/kg/h for 96 h)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411